Royal Bank Of Canada Scynexis Inc Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.93 - $3.64 $32,238 - $60,802	16,704 Added 17400.0%	16,800 $38,000
Q2 2023 Aug 14, 2023	SELL	$2.38 - $3.67 $961 - $1,482	-404 Reduced 80.8%	96 $0
Q1 2023 May 15, 2023	BUY	$1.15 - $3.0 $402 - $1,050	350 Added 233.33%	500 $1,000
Q4 2022 Feb 14, 2023	SELL	$1.46 - $2.94 $5 - $11	-4 Reduced 2.6%	150 $0
Q3 2022 Nov 14, 2022	BUY	$1.83 - $2.93 $281 - $451	154 New	154 $0
Q2 2022 Aug 15, 2022	SELL	$1.77 - $3.87 $725 - $1,586	-410 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.5 - $9.97 $2,665 - $4,087	410 New	410 $3,000

13.7M

21.9K

2.6K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $33M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.